Compare NNVC & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | PRPH |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 4.1M |
| IPO Year | N/A | 1997 |
| Metric | NNVC | PRPH |
|---|---|---|
| Price | $1.21 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 325.4K | ★ 2.6M |
| Earning Date | 02-13-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.94 | $0.41 |
| 52 Week High | $2.23 | $9.35 |
| Indicator | NNVC | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 50.11 |
| Support Level | $1.20 | $0.41 |
| Resistance Level | $1.31 | $1.15 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 41.38 | 23.64 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.